DEVELOPING TRENDS IN THE SPECIALTY DRUG PIPELINE
"Six specialty classes are maturing, including HIV, multiple sclerosis (MS), and drugs for psoriasis, and there is a $25 billion market opportunity through 2022 as 64 drugs come off patent protection. Likewise, there is a similar opportunity in biosimiliars, as 71 patents lose protection through 2021, creating a $54.4 billion market. There are 10 biosimiliars pending approval this year, targeting treatments for anemia, breast cancer, neutropenia, rheumatoid arthritis (RA), non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), and psoriasis."